Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias

Leukemia

Volumn 18, Issue 4, 2004, Pages 734-742

  Vandenberghe, Peter ^a   Wlodarska, I ^a   Michaux, L ^b   Zachee P ^c   Boogaerts, M ^a   Vanstraelen, D ^d   Herregods, M C ^a   Van Hoof, A ^e   Selleslag, D ^e   Roufosse, F ^f   Maerevoet, M ^b   Verhoef, G ^a   Cools, J ^g   Gilliland, D G ^g   Hagemeijer, A ^a   Marynen, Peter ^h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c Stuivenberg General Hospital   (Belgium)

^d VIRGA JESSE HOSPITAL   (Belgium)

^e General Hospital St Jan   (Belgium)

^f ERASME HOSPITAL   (Belgium)

^g HARVARD MEDICAL SCHOOL   (United States)

^h DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Chronic eosinophilic leukemia; FIP1L1 PDGFRA; Idiopathic hypereosinophilic syndrome; Imatinib

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; HYBRID PROTEIN; HYDROXYUREA; IDARUBICIN; IMATINIB; MERCAPTOPURINE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISONE; STEROID; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST; ENDOCARDITIS; EOSINOPHILIC LEUKEMIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE DELETION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; MALE; MYELOPROLIFERATIVE DISORDER; PATIENT MONITORING; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENOMEGALY; VITAMIN BLOOD LEVEL; WORLD HEALTH ORGANIZATION;

EID: 3042678647     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403313     Document Type: Article

References (21)

1. Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol 1996; 95: 2-9.
2. Bain BJ. Hypereosinophilia. Curr Opin Hematol 2000; 7: 21-25.
3. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27.
4. Bain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G. Chronic eosinophilic leukemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Vardiman JW (eds) WHO Classification of Tumours: Pathology and Genetics. Tumors of Haematopoietic and Lymphoid tissues. Lyon: IARC Press, 2001, pp 29-31.
5. Zittoun J, Farcet JP, Marquet J, Sultan C, Zittoun R. Cobalamin (vitamin B12) and B12 binding proteins in hypereosinophilic syndromes and secondary eosinophilia. Blood 1984; 63: 779-783.
6. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97: 78-92.
7. Weller P, Bubley G. The idiopathic hypereosinophilic syndrome. Blood 1494; 83: 2759-2779.
8. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
9. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. PG459-69. Cancer Cell 2003; 5: 459-469.
10. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577-1578.
11. Pardanani A, Reeder T, Porrata LF, Li C-Y, Tazelaar HD, Baxter EJ et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101: 3391-3397.
12. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003; 101: 4714-4716.
13. Malbrain ML, Van den Bergh H, Zachee P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol 1996; 92: 176-183.
14. Mitelman F, ISCN. An International System for Human Cytogenetic Nomenclature. Basel: S Karger, 1995.
15. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3, RESEARCH0034.1-0034.11.
16. Cools J, Quentmeier H, Huntly BJ, Marynen P, Griffin JD, Drexler HG et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 2003, Nov 20 [Epub ahead of print], in press.
17. Martin-Subero JI, Harder L, Gesk S, Schlegelberger B, Grote W, Martinez-Climent JA et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 2002; 98: 470-474.
18. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 3093-3096.
19. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660-4666.
20. Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndrome. N Engl J Med 2003; 348: 2687.
21. Valent P, Horny HP, Li CY, Longley BJ, Metcalfe DD, Parwaresch RM et al. Mastocytosis. In: Jaffe ES, Harris NL, Vardiman JW (eds) WHO Classification of Tumours: Pathology and Genetics. Tumors of Haematopoietic and Lymphoid tissues. Lyon: IARC Press, 2001, pp 292-302.